Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes

NCT02016846 on ClinicalTrials.gov · last registry update 2013-12-24

A small phase 3 — 36 participants, against a typical 424. Its estimated completion date, January 2015, has passed with no update to the record. Primary outcome, as filed: Glucose levels 2 hours after 75 gr OGTT. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here.

Status: UNKNOWN
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Rabin Medical Center
Sponsor type: Other
Enrollment: 36
Started: 2014-01
Primary completion: 2015-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Glucose levels 2 hours after 75 gr OGTT

Conditions studied

Glucocorticoid Induced Hyperglycemia

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.